Oncolytic Adenovirus in Phase 1 has extended half-life TGF-ß trap LA JOLLA, Calif., December 8, 2021 -- EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other...
2021
EpicentRx Granted New Composition of Matter Patent for Its TGF-ß Trap Fusion Protein
LA JOLLA, Calif., Nov. 22, 2021 -- EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that the United States Patent and...
EpicentRx Announces Completion of First Cohort in Phase 1 “BETA PRIME” Trial with AdAPT-001
Cancer-targeting adenovirus enhanced with a TGFβ Trap well tolerated in patients with advanced cancer TORREY PINES, Calif., Sept. 29, 2021 -- EpicentRx Inc., a leading-edge drug and device company with cancer and inflammatory disease-targeted platforms, today...
EpicentRx, Inc. in an Expansive Growth Phase
Company secures 10M US dollar growth capital term loan from Silicon Valley Bank (SVB) to accelerate development of immunotherapies for cancer AdAPT-001, a TGF-beta trap expressing oncolytic virus, designed to activate the immune system and improve checkpoint...